{"groups":[{"description":"Participants were randomized to 6 mg/kg panitumumab intravenous infusion plus a standard chemotherapy regimen (FOLFIRI) consisting of 5-FU, leucovorin and irinotecan. Treatment was administered in cycles every two weeks.","id":"FG000","title":"Panitumumab Plus FOLFIRI"},{"description":"Participants were randomized to receive a standard chemotherapy regimen (FOLFIRI) consisting of 5-FU, leucovorin and irinotecan. Treatment was administered in cycles every two weeks.","id":"FG001","title":"FOLFIRI Alone"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"3"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"19"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"4"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"17"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"8"}],"type":"Protocol-specified criteria"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"1"}],"type":"Missing reason"},{"reasons":[{"groupId":"FG000","numSubjects":"46"},{"groupId":"FG001","numSubjects":"40"}],"type":"Other"},{"reasons":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"13"}],"type":"Ongoing"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"591"},{"groupId":"FG001","numSubjects":"595"}],"type":"STARTED"},{"achievements":[{"comment":"Includes one participant who received FOLFIRI Alone","groupId":"FG000","numSubjects":"588"},{"groupId":"FG001","numSubjects":"593"}],"type":"Received Study Drug"},{"achievements":[{"comment":"Indicates participants who had completed the safety visit 30 days after last dose or had died","groupId":"FG000","numSubjects":"470"},{"comment":"Indicates participants who had completed the safety visit 30 days after last dose or had died","groupId":"FG001","numSubjects":"490"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"121"},{"groupId":"FG001","numSubjects":"105"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"First patient enrolled 30 June 2006; Last patient enrolled 13 March 2008."}